Test, Treat, Repeat: Closing Persistent Gaps in HCV Care

Please visit answersincme.com/860/101064703-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Muthiah Vaduganathan, MD, MPH and Nosheen Reza, MD, MS. In this activity, experts in cardio-kidney-metabolic syndrome (CKM) discuss emerging evidence on nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) and practical strategies for incorporating these therapies into care for patients with heart failure, with or without chronic kidney disease (CKD) or type 2 diabetes (T2D). Upon completion of this activity, participants should be better able to: Specify the rationale for nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) as treatment for adult patients with HF, with or without CKD or T2D; Differentiate the risk-benefit profiles between nsMRAs and the current standard of care for the treatment of HFmrEF or HFpEF, based on the available evidence; and Recommend patient-centered, long-term care strategies to integrate nsMRAs into clinical practice for patients with HF, with or without overlapping CKD or T2D.

Please visit answersincme.com/860/102620367-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Keith C. Ferdinand, MD; and Henry J. Michtalik, MD, MPH, MHS. IIn this activity, experts in preventive cardiology and hospital medicine discuss secondary stroke prevention strategies for hospitalists and internists. Upon completion of this activity, participants should be better able to: Evaluate guideline-recommended secondary stroke prevention strategies after ischemic stroke or TIA; Describe the clinical rationale for FXIa inhibitors; Discuss the clinical significance of the latest efficacy and safety data for FXIa inhibitors in secondary stroke prevention; and Apply best practices for transitioning patients from inpatient to outpatient secondary stroke prevention care.

Please visit answersincme.com/QSK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Markus Cornberg, MD. In this activity, an expert in infectious diseases discusses the management of patients with hepatitis C virus (HCV) infection. Upon completion of this activity, participants should be better able to: Discuss the factors influencing timely intervention in hepatitis C virus (HCV) management; Describe recommended HCV screening strategies to increase uptake in underserved populations; and Recognize appropriate criteria for initiating simplified HCV therapy or referring patients for specialist care.

Please visit answersincme.com/FGV860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Janet B. McGill, MD, MA, FACP, MACE. In this activity, an expert in the management of diabetes discusses evolving data on emerging strategies to enhance cardiorenal outcomes in patients with type 1 diabetes (T1D). Upon completion of this activity, participants should be better able to: Review the limitations of current treatment strategies for chronic kidney disease (CKD) in type 1 diabetes (T1D); Identify the pathophysiologic mechanisms underlying CKD in patients with T1D; and Assess current and emerging treatment strategies for their potential to improve cardiorenal outcomes in patients with T1D.

Please visit answersincme.com/KQK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Virginia Clark, MD, MS. In this activity, an expert in liver disease discusses practical considerations for identifying and managing liver disease related to alpha-1 antitrypsin deficiency (AATD) across the care continuum. Upon completion of this activity, participants should be better able to: Apply strategies to reach a diagnosis of AATD and associated liver disease; Summarize the evolving treatment landscape for AATD-associated liver disease; and Explain multidisciplinary team approaches to effectively manage patients with AATD-associated liver disease.

Please visit answersincme.com/AGN860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ferhina Ali, MD, MPH, FASRS. In this activity, an expert in retinal diseases discusses anti-VEGF treatment of diabetic macular edema. Upon completion of this activity, participants should be better able to: Recognize factors that contribute to patients' treatment burden with intravitreal anti–vascular endothelial growth factor (VEGF) therapies for diabetic macular edema (DME); Assess the clinical profiles of long-acting intravitreal anti-VEGF agents for DME; and Recommend individualized strategies to enhance long-term treatment outcomes for patients with DME.

Please visit answersincme.com/KWA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Benjamin Levy, MD, FASCO. In this activity, an expert in oncology discusses the use of subcutaneous immune checkpoint inhibitors. Upon completion of this activity, participants should be better able to: Describe the rationale for subcutaneous (SC) immune checkpoint inhibitor (ICI) administration in the context of standard care with intravenous (IV) formulations in patients with advanced solid tumors; Review the evidence for SC formulations of ICIs compared with IV formulations in patients with advanced solid tumors; and Propose patient-centered strategies for enhancing care with SC administration of ICIs in patients with advanced solid tumors.

Please visit answersincme.com/SST860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jennifer Vittorio, MD, FAASLD. In this activity, an expert in hepatology discusses the treatment of cholestatic pruritus. Upon completion of this activity, participants should be better able to: Explain the rationale for new treatment strategies for the management of cholestatic pruritus; Evaluate clinical trial data and safety profiles of new and emerging ileal bile acid transporter (IBAT) inhibitors; and Implement best practices for patient selection and initiation of IBAT inhibitor therapy.

Please visit answersincme.com/HAC860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Kohei Shitara, MD, PhD. In this activity, an expert in gastrointestinal oncology discusses the latest data for the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma. Upon completion of this activity, participants should be better able to: Discuss the latest efficacy and safety data for HER2-directed antibody-drug conjugates in the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma; and Translate the latest data for the treatment of gastric and GEJ adenocarcinoma within the context of the current treatment landscape.

Please visit answersincme.com/860/240201375-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by James Michael Ramsahai, BSc, MD, PhD, FRCPC and Nan Zhao, BSc, MD, FRCPC. In this activity, experts in managing severe eosinophilic asthma discuss evidence-based strategies for personalizing biologic therapy, reducing steroid burden, and optimizing treatment in the setting of overlapping eosinophilic diseases. Upon completion of this activity, participants should be better able to: Identify strategies to individualize the selection of biologic therapies for patients with severe eosinophilic asthma based on the latest clinical and real-world evidence; Evaluate the implications of real-world data on biologic therapies for addressing airway remodeling and airway plugging; Develop steroid-sparing treatment plans and monitoring strategies for patients with severe eosinophilic asthma; and Formulate treatment plans to adjust the use of biologic therapies in patients with severe eosinophilic asthma and overlapping eosinophilic comorbidities.